The Epidemiology of Nonalcoholic Fatty Liver Disease: A Global Perspective

Mariana Lazo; Jeanne M. Clark

doi:10.1055/s-0028-1091978

Seminars in Liver Disease, Table of Contents

Semin Liver Dis 2008; 28(4): 339-350
DOI: 10.1055/s-0028-1091978

The Epidemiology of Nonalcoholic Fatty Liver Disease: A Global Perspective

Mariana Lazo¹ ^, ² , Jeanne M. Clark¹ ^, ² ^, ³

¹Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
²Welch Center for Prevention, Epidemiology, and Clinical Research, Baltimore, Maryland
³Department of Medicine, Johns Hopkins University, Baltimore, Maryland

Abstract

ABSTRACT

Nonalcoholic fatty liver disease (NAFLD) is an increasingly recognized cause of liver disease in the United States and worldwide. With obesity being an important risk factor universally, NAFLD is now receiving greater attention and is regarded as a public health issue. In addition, as a result of an aging population and the improving control of other major causes of chronic liver disease, such as hepatitis C and hepatitis B, the burden of NAFLD is expected to increase in years to come. Prevalence estimates of this disease vary widely across populations because of differences in methods for diagnosis and/or definition. New strategies for the prevention, diagnosis, and management will be required to alter the course of this disease.

KEYWORDS

Nonalcoholic fatty liver disease - NAFLD - epidemiology - risk factors

Full Text

References

REFERENCES

1 Brunt E M. Nonalcoholic steatohepatitis. Semin Liver Dis. 2004; 24(1) 3-20
2 Bugianesi E, Leone N, Vanni E et al.. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002; 123(1) 134-140
3 Clark J M, Diehl A M. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA. 2003; 289(22) 3000-3004
4 Abdelmalek M F, Diehl A M. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin North Am. 2007; 91(6) 1125-1149 , ix
5 Brunt E M. Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. Semin Diagn Pathol. 2005; 22(4) 330-338
6 Ogden C L, Carroll M D, Curtin L R, McDowell M A, Tabak C J, Flegal K M. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA. 2006; 295(13) 1549-1555
7 Clark J M. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006; 40(suppl 1) S5-S10
8 Falck-Ytter Y, Younossi Z M, Marchesini G, McCullough A J. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis. 2001; 21(1) 17-26
9 Neuschwander-Tetri B A, Caldwell S H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003; 37(5) 1202-1219
10 Yeh M M, Brunt E M. Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol. 2007; 128(5) 837-847
11 Ratziu V, Charlotte F, Heurtier A et al.. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005; 128(7) 1898-1906
12 Mofrad P, Contos M J, Haque M et al.. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003; 37(6) 1286-1292
13 Yano E, Tagawa K, Yamaoka K, Mori M. Test validity of periodic liver function tests in a population of Japanese male bank employees. J Clin Epidemiol. 2001; 54(9) 945-951
14 Lazo M, Selvin E, Clark J M. Brief Communication: Clinical implications of short-term variability in liver function test results. Ann Intern Med. 2008; 148 348-352
15 Clark J M, Brancati F L, Diehl A M. Nonalcoholic fatty liver disease. Gastroenterology. 2002; 122(6) 1649-1657
16 Strauss S, Gavish E, Gottlieb P, Katsnelson L. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR Am J Roentgenol. 2007; 189(6) W320-W323
17 Szczepaniak L S, Nurenberg P, Leonard D et al.. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005; 288(2) E462-E468
18 Clouston A D, Jonsson J R, Powell E E. Steatosis as a cofactor in other liver diseases: hepatitis C virus, alcohol, hemochromatosis, and others. Clin Liver Dis. 2007; 11(1) 173-189 , x
19 Adinolfi L E, Gambardella M, Andreana A, Tripodi M F, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001; 33(6) 1358-1364
20 Friedenberg F, Pungpapong S, Zaeri N, Braitman L E. The impact of diabetes and obesity on liver histology in patients with hepatitis C. Diabetes Obes Metab. 2003; 5(3) 150-155
21 Lonardo A, Adinolfi L E, Loria P, Carulli N, Ruggiero G, Day C P. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology. 2004; 126(2) 586-597
22 Patton H M, Patel K, Behling C et al.. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol. 2004; 40(3) 484-490
23 Pekow J R, Bhan A K, Zheng H, Chung R T. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer. 2007; 109(12) 2490-2496
24 Ramesh S, Sanyal A J. Hepatitis C and nonalcoholic fatty liver disease. Semin Liver Dis. 2004; 24(4) 399-413
25 Leandro G, Mangia A, Hui J et al.. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006; 130(6) 1636-1642
26 Thomopoulos K C, Arvaniti V, Tsamantas A C et al.. Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis. Eur J Gastroenterol Hepatol. 2006; 18(3) 233-237
27 Hadigan C, Liebau J, Andersen R, Holalkere N S, Sahani D V. Magnetic resonance spectroscopy of hepatic lipid content and associated risk factors in HIV infection. J Acquir Immune Defic Syndr. 2007; 46(3) 312-317
28 Clouston A D, Powell E E. Interaction of non-alcoholic fatty liver disease with other liver diseases. Best Pract Res Clin Gastroenterol. 2002; 16(5) 767-781
29 Zhou Y J, Li Y Y, Nie Y Q et al.. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol. 2007; 13(47) 6419-6424
30 Fan J G, Li F, Cai X B, Peng Y D, Ao Q H, Gao Y. The importance of metabolic factors for the increasing prevalence of fatty liver in Shanghai factory workers. J Gastroenterol Hepatol. 2007; 22(5) 663-668
31 Lin T J, Lin C L, Wang C S, Liu S O, Liao L Y. Prevalence of HFE mutations and relation to serum iron status in patients with chronic hepatitis C and patients with nonalcoholic fatty liver disease in Taiwan. World J Gastroenterol. 2005; 11(25) 3905-3908
32 Fan J G, Zhu J, Li X J et al.. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol. 2005; 43(3) 508-514
33 Shen L, Fan J G, Shao Y et al.. Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World J Gastroenterol. 2003; 9(5) 1106-1110
34 Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int. 2006; 26(7) 856-863
35 Kagansky N, Levy S, Keter D et al.. Non-alcoholic fatty liver disease: a common and benign finding in octogenarian patients. Liver Int. 2004; 24(6) 588-594
36 Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 2005; 42(1) 44-52
37 Hamaguchi M, Kojima T, Takeda N et al.. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005; 143(10) 722-728
38 Jimba S, Nakagami T, Takahashi M et al.. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med. 2005; 22(9) 1141-1145
39 Omagari K, Kadokawa Y, Masuda J et al.. Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol. 2002; 17(10) 1098-1105
40 Kim H J, Kim H J, Lee K E et al.. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med. 2004; 164(19) 2169-2175
41 Lizardi-Cervera J, Laparra D I, Chavez-Tapia N C, Ostos M E, Esquivel M U. Prevalence of NAFLD and metabolic syndrome in asymtomatics subjects. Rev Gastroenterol Mex. 2006; 71(4) 453-459
42 Chen C H, Huang M H, Yang J C et al.. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol. 2006; 40(8) 745-752
43 Park S H, Jeon W K, Kim S H et al.. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol. 2006; 21(1) 138-143
44 Lin Y C, Lo H M, Chen J D. Sonographic fatty liver, overweight and ischemic heart disease. World J Gastroenterol. 2005; 11(31) 4838-4842
45 Church T S, Kuk J L, Ross R, Priest E L, Biltoft E, Blair S N. Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. Gastroenterology. 2006; 130(7) 2023-2030
46 Browning J D, Szczepaniak L S, Dobbins R et al.. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40(6) 1387-1395
47 Pendino G M, Mariano A, Surace P et al.. Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town. Hepatology. 2005; 41(5) 1151-1159
48 Suzuki A, Angulo P, Lymp J et al.. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology. 2005; 41(1) 64-71
49 Clark J M, Brancati F L, Diehl A M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003; 98(5) 960-967
50 Ruhl C E, Everhart J E. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 2003; 124(1) 71-79
51 Amarapurkar A, Ghansar T. Fatty liver: experience from western India. Ann Hepatol. 2007; 6(1) 37-40
52 Yamamoto K, Takada Y, Fujimoto Y et al.. Nonalcoholic steatohepatitis in donors for living donor liver transplantation. Transplantation. 2007; 83(3) 257-262
53 Brunt E M, Janney C G, Di Bisceglie A M et al.. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999; 94 2467-2474
54 Halon A, Patrzalek D, Rabczynski J. Hepatic steatosis in liver transplant donors: rare phenomenon or common feature of donor population?. Transplant Proc. 2006; 38(1) 193-195
55 Tran T T, Changsri C, Shackleton C R et al.. Living donor liver transplantation: histological abnormalities found on liver biopsies of apparently healthy potential donors. J Gastroenterol Hepatol. 2006; 21(2) 381-383
56 Omagari K, Kadokawa Y, Masuda J et al.. Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol. 2002; 17(10) 1098-1105
57 Bedogni G, Miglioli L, Masutti F et al.. Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology. 2007; 46(5) 1387-1391
58 Ground K E. Liver pathology in aircrew. Aviat Space Environ Med. 1982; 53(1) 14-18
59 Underwood Ground K E. Prevalence of fatty liver in healthy male adults accidentally killed. Aviat Space Environ Med. 1984; 55(1) 59-61
60 Hilden M, Christoffersen P, Juhl E, Dalgaard J B. Liver histology in a “normal” population: examinations of 503 consecutive fatal traffic casualties. Scand J Gastroenterol. 1977; 12(5) 593-597
61 Targher G, Bertolini L, Padovani R et al.. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007; 30(5) 1212-1218
62 Angelico F, Del B M, Conti R et al.. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2005; 90(3) 1578-1582
63 Gupte P, Amarapurkar D, Agal S et al.. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol. 2004; 19(8) 854-858
64 Roesch-Dietlen F, Dorantes-Cuellar A, Carrillo-Toledo M G et al.. Frequency of NAFLD in a group of patients with metabolic syndrome in Veracruz, Mexico. Rev Gastroenterol Mex. 2006; 71(4) 446-452
65 Gambarin-Gelwan M, Kinkhabwala S V, Schiano T D, Bodian C, Yeh H C, Futterweit W. Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol. 2007; 5(4) 496-501
66 Weston S R, Leyden W, Murphy R et al.. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology. 2005; 41(2) 372-379
67 Liangpunsakul S, Chalasani N. Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III). Am J Med Sci. 2005; 329(3) 111-116
68 Lima M L, Mourao S C, Diniz M T, Leite V H. Hepatic histopathology of patients with morbid obesity submitted to gastric bypass. Obes Surg. 2005; 15(5) 661-669
69 de Oliveira C P, de Mello E S, Alves V A, Saviero S M, Strauss E. Changes in histological criteria lead to different prevalences of nonalcoholic steatohepatitis in severe obesity. Ann Hepatol. 2007; 6(4) 255-261
70 Boza C, Riquelme A, Ibanez L et al.. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes Surg. 2005; 15(8) 1148-1153
71 Harnois F, Msika S, Sabate J M et al.. Prevalence and predictive factors of non-alcoholic steatohepatitis (NASH) in morbidly obese patients undergoing bariatric surgery. Obes Surg. 2006; 16(2) 183-188
72 Wolf A M, Busch B, Kuhlmann H W, Beisiegel U. Histological changes in the liver of morbidly obese patients: correlation with metabolic parameters. Obes Surg. 2005; 15(2) 228-237
73 Papadia F S, Marinari G M, Camerini G et al.. Liver damage in severely obese patients: a clinical-biochemical-morphologic study on 1,000 liver biopsies. Obes Surg. 2004; 14(7) 952-958
74 Sorrentino P, Tarantino G, Conca P et al.. Silent non-alcoholic fatty liver disease: a clinical-histological study. J Hepatol. 2004; 41(5) 751-757
75 Chavarria-Arciniega S, Lopez-Alvarenga J C, Uribe-Uribe N O, Herrera-Hernandez M, Gonzalez-Barranco J. Relationship between morphological diagnosis of NASH (non-alcoholic steatohepatitis) and liver function tests in a group of patients with morbid obesity. Rev Invest Clin. 2005; 57(4) 505-512
76 Liew P L, Lee W J, Lee Y C, Wang H H, Wang W, Lin Y C. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease. Obes Surg. 2006; 16(12) 1584-1593
77 Kleiner D E, Brunt E M, Van Natta M et al.. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41 1313-1321
78 Gholam P M, Flancbaum L, Machan J T, Charney D A, Kotler D P. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol. 2007; 102(2) 399-408
79 Solga S F, Clark J M, Alkhuraishi A R et al.. Race and comorbid factors predict nonalcoholic fatty liver disease histopathology in severely obese patients. Surg Obes Relat Dis. 2005; 1(1) 6-11
80 Kunde S S, Lazenby A J, Clements R H, Abrams G A. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology. 2005; 42(3) 650-656
81 Abrams G A, Kunde S S, Lazenby A J, Clements R H. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology. 2004; 40(2) 475-483
82 Beymer C, Kowdley K V, Larson A, Edmonson P, Dellinger E P, Flum D R. Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Arch Surg. 2003; 138(11) 1240-1244
83 Spaulding L, Trainer T, Janiec D. Prevalence of non-alcoholic steatohepatitis in morbidly obese subjects undergoing gastric bypass. Obes Surg. 2003; 13(3) 347-349
84 Ong J P, Elariny H, Collantes R et al.. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg. 2005; 15(3) 310-315
85 Albano E, Mottaran E, Vidali M et al.. Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut. 2005; 54(7) 987-993
86 Angelico F, Del B M, Conti R et al.. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2005; 90(3) 1578-1582
87 Kelley D E, McKolanis T M, Hegazi R A, Kuller L H, Kalhan S C. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab. 2003; 285(4) E906-E916
88 Kotronen A, Juurinen L, Hakkarainen A et al.. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care. 2008; 31(1) 165-169
89 Guha I N, Parkes J, Roderick P R, Harris S, Rosenberg W M. Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut. 2006; 55(11) 1650-1660
90 Angulo P, Keach J C, Batts K P, Lindor K D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999; 30(6) 1356-1362
91 Dixon J B, Bhathal P S, O'Brien P E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001; 121(1) 91-100
92 Mofrad P, Contos M J, Haque M et al.. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003; 37(6) 1286-1292
93 Sheth S G, Gordon F D, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med. 1997; 126(2) 137-145
94 Carulli L, Lonardo A, Lombardini S, Marchesini G, Loria P. Gender, fatty liver and GGT. Hepatology. 2006; 44(1) 278-279
95 McKenzie J, Fisher B M, Jaap A J, Stanley A, Paterson K, Sattar N. Effects of HRT on liver enzyme levels in women with type 2 diabetes: a randomized placebo-controlled trial. Clin Endocrinol (Oxf). 2006; 65(1) 40-44
96 Enzi G, Gasparo M, Biondetti P R, Fiore D, Semisa M, Zurlo F. Subcutaneous and visceral fat distribution according to sex, age, and overweight, evaluated by computed tomography. Am J Clin Nutr. 1986; 44(6) 739-746
97 Lemieux S, Prud'homme D, Bouchard C, Tremblay A, Despres J P. Sex differences in the relation of visceral adipose tissue accumulation to total body fatness. Am J Clin Nutr. 1993; 58(4) 463-467
98 Petersen K F, Befroy D, Dufour S et al.. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science. 2003; 300(5622) 1140-1142
99 Fink R I, Kolterman O G, Griffin J, Olefsky J M. Mechanisms of insulin resistance in aging. J Clin Invest. 1983; 71(6) 1523-1535
100 Caldwell S H, Harris D M, Patrie J T, Hespenheide E E. Is NASH underdiagnosed among African Americans?. Am J Gastroenterol. 2002; 97(6) 1496-1500
101 Caldwell S H, Ikura Y, Iezzoni J C, Liu Z. Has natural selection in human populations produced two types of metabolic syndrome (with and without fatty liver)?. J Gastroenterol Hepatol. 2007; 22(suppl 1) S11-S19
102 Amarapurkar D N, Hashimoto E, Lesmana L A, Sollano J D, Chen P J, Goh K L. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences?. J Gastroenterol Hepatol. 2007; 22(6) 788-793
103 Petersen K F, Dufour S, Feng J et al.. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci U S A. 2006; 103(48) 18273-18277
104 Kotronen A, Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008; 28(1) 27-38
105 Ikai E, Ishizaki M, Suzuki Y, Ishida M, Noborizaka Y, Yamada Y. Association between hepatic steatosis, insulin resistance and hyperinsulinaemia as related to hypertension in alcohol consumers and obese people. J Hum Hypertens. 1995; 9(2) 101-105
106 Kang H, Greenson J K, Omo J T et al.. Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. Am J Gastroenterol. 2006; 101(10) 2247-2253
107 Marchesini G, Bugianesi E, Forlani G et al.. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003; 37(4) 917-923
108 Jakobsen M U, Berentzen T, Sorensen T I, Overvad K. Abdominal obesity and fatty liver. Epidemiol Rev. 2007; 29 77-87
109 Bellentani S, Bedogni G, Miglioli L, Tiribelli C. The epidemiology of fatty liver. Eur J Gastroenterol Hepatol. 2004; 16(11) 1087-1093
110 Diehl A M. Hepatic complications of obesity. Gastroenterol Clin North Am. 2005; 34(1) 45-61
111 Bellentani S, Saccoccio G, Masutti F et al.. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000; 132(2) 112-117
112 Nair S, Mason A, Eason J, Loss G, Perrillo R P. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?. Hepatology. 2002; 36(1) 150-155
113 Norman D, Bardwell W A, Arosemena F et al.. Serum aminotransferase levels are associated with markers of hypoxia in patients with obstructive sleep apnea. Sleep. 2008; 31(1) 121-126
114 Kallwitz E R, Herdegen J, Madura J, Jakate S, Cotler S J. Liver enzymes and histology in obese patients with obstructive sleep apnea. J Clin Gastroenterol. 2007; 41(10) 918-921
115 Acarturk G, Unlu M, Yuksel S, Albayrak R, Koken T, Peker Y. Obstructive sleep apnoea, glucose tolerance and liver steatosis in obese women. J Int Med Res. 2007; 35(4) 458-466
116 Singh H, Pollock R, Uhanova J, Kryger M, Hawkins K, Minuk G Y. Symptoms of obstructive sleep apnea in patients with nonalcoholic fatty liver disease. Dig Dis Sci. 2005; 50(12) 2338-2343
117 Savransky V, Nanayakkara A, Vivero A et al.. Chronic intermittent hypoxia predisposes to liver injury. Hepatology. 2007; 45(4) 1007-1013
118 Zamora-Valdes D, Mendez-Sanchez N. Experimental evidence of obstructive sleep apnea syndrome as a second hit accomplice in nonalcoholic steatohepatitis pathogenesis. Ann Hepatol. 2007; 6(4) 281-283
119 Tanne F, Gagnadoux F, Chazouilleres O et al.. Chronic liver injury during obstructive sleep apnea. Hepatology. 2005; 41(6) 1290-1296
120 Abdelmalek M F, Liu C, Shuster J, Nelson D R, Asal N R. Familial aggregation of insulin resistance in first-degree relatives of patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2006; 4(9) 1162-1169
121 Willner I R, Waters B, Patil S R, Reuben A, Morelli J, Riely C A. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol. 2001; 96(10) 2957-2961
122 Browning J D, Kumar K S, Saboorian M H, Thiele D L. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol. 2004; 99(2) 292-298
123 Struben V M, Hespenheide E E, Caldwell S H. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med. 2000; 108(1) 9-13
124 Wilfred de Alwis N M, Day C P. Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin Liver Dis. 2007; 27(1) 44-54
125 Day C P. The potential role of genes in nonalcoholic fatty liver disease. Clin Liver Dis. 2004; 8(3) 673-691
126 Cave M, Deaciuc I, Mendez C et al.. Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. J Nutr Biochem. 2007; 18(3) 184-195
127 Jenkins D J, Josse A R, Labelle R, Marchie A, Augustin L S, Kendall C W. Nonalcoholic fatty liver, nonalcoholic steatohepatitis, ectopic fat, and the glycemic index. Am J Clin Nutr. 2006; 84(1) 3-4
128 Solga S, Alkhuraishe A R, Clark J M et al.. Dietary composition and nonalcoholic fatty liver disease. Dig Dis Sci. 2004; 49(10) 1578-1583
129 Toshimitsu K, Matsuura B, Ohkubo I et al.. Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition. 2007; 23(1) 46-52
130 Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R et al.. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol. 2007; 47(5) 711-717
131 Solga S F, Diehl A M. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol. 2003; 38(5) 681-687
132 Solga S F, Diehl A M. Gut flora-based therapy in liver disease? The liver cares about the gut. Hepatology. 2004; 39(5) 1197-1200
133 Wigg A J, Roberts-Thomson I C, Dymock R B, McCarthy P J, Grose R H, Cummins A G. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut. 2001; 48(2) 206-211
134 Ekstedt M, Franzen L E, Mathiesen U L et al.. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006; 44(4) 865-873
135 Hashimoto E, Yatsuji S, Kaneda H et al.. The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. Hepatol Res. 2005; 33(2) 72-76
136 Hui J M, Kench J G, Chitturi S et al.. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology. 2003; 38(2) 420-427
137 Sanyal A J, Banas C, Sargeant C et al.. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology. 2006; 43(4) 682-689
138 Sanyal A J. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002; 123(5) 1705-1725
139 Villanova N, Moscatiello S, Ramilli S et al.. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology. 2005; 42(2) 473-480
140 Volzke H, Robinson D M, Kleine V et al.. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol. 2005; 11(12) 1848-1853
141 Stranges S, Trevisan M, Dorn J M, Dmochowski J, Donahue R P. Body fat distribution, liver enzymes, and risk of hypertension: evidence from the Western New York Study. Hypertension. 2005; 46(5) 1186-1193
142 Hanley A J, Williams K, Festa A et al.. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2004; 53(10) 2623-2632
143 Hanley A J, Williams K, Festa A, Wagenknecht L E, D'Agostino Jr R B, Haffner S M. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes. 2005; 54(11) 3140-3147

Mariana Lazo M.D. M.Sc.

Welch Center for Prevention, Epidemiology, and Clinical Research

2024 E. Monument Street, Suite 2-600, Baltimore, MD 21205-2223

Email: mlazo@jhsph.edu